# Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers

> **NCT01202240** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tasocitinib (CP-690,55) plus Ketoconazole

## Key facts

- **NCT ID:** NCT01202240
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2011-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202240, "Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01202240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*